Literature DB >> 11898943

Advances in the pharmacotherapy of Alzheimer's disease.

Serge Gauthier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11898943      PMCID： PMC99406     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  30 in total

Review 1.  Alzheimer's disease: current and future therapeutic perspectives.

Authors:  S Gauthier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2001-01       Impact factor: 5.067

Review 2.  Recommendations for the management of behavioral and psychological symptoms of dementia.

Authors:  N Herrmann
Journal:  Can J Neurol Sci       Date:  2001-02       Impact factor: 2.104

Review 3.  Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

Authors:  B Winblad; H Brodaty; S Gauthier; J C Morris; J M Orgogozo; K Rockwood; L Schneider; M Takeda; P Tariot; D Wilkinson
Journal:  Int J Geriatr Psychiatry       Date:  2001-07       Impact factor: 3.485

4.  Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers.

Authors:  J C Morris; M R Farlow; S H Ferris; A F Kurz; A Maelicke; L Rasmusen; D Wilkinson; B Yan
Journal:  Clin Ther       Date:  2001       Impact factor: 3.393

Review 5.  The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia.

Authors:  C Patterson; S Gauthier; H Bergman; C Cohen; J W Feightner; H Feldman; A Grek; D B Hogan
Journal:  Can J Neurol Sci       Date:  2001-02       Impact factor: 2.104

6.  The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease.

Authors:  H Feldman; A Sauter; A Donald; I Gélinas; S Gauthier; K Torfs; W Parys; A Mehnert
Journal:  Alzheimer Dis Assoc Disord       Date:  2001 Apr-Jun       Impact factor: 2.703

7.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.

Authors:  G K Wilcock; S Lilienfeld; E Gaens
Journal:  BMJ       Date:  2000-12-09

8.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

Authors:  M A Raskind; E R Peskind; T Wessel; W Yuan
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

9.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

10.  The effects of donepezil in Alzheimer's disease - results from a multinational trial.

Authors:  A Burns; M Rossor; J Hecker; S Gauthier; H Petit; H J Möller; S L Rogers; L T Friedhoff
Journal:  Dement Geriatr Cogn Disord       Date:  1999 May-Jun       Impact factor: 2.959
View more
  17 in total

Review 1.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

2.  Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil.

Authors:  Kristin Huse Haug; Inger Lise Bogen; Harald Osmundsen; Ivar Walaas; Frode Fonnum
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 3.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

4.  Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-11-26       Impact factor: 8.262

Review 5.  Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

Authors:  Krista L Lanctôt; Nathan Herrmann; Maysoon M LouLou
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

6.  Senile Dementia from Neuroscientific and Islamic Perspectives.

Authors:  Mohd Amzari Tumiran; Noor Naemah Abdul Rahman; Rohaida Mohd Saat; Ahmad Zuhdi Ismail; Wan Adriyani Wan Ruzali; Nurul Kabir Nurul Bashar; Durriyyah Sharifah Hasan Adli
Journal:  J Relig Health       Date:  2018-02

7.  Early-stage memory loss support groups: outcomes from a randomized controlled clinical trial.

Authors:  Rebecca G Logsdon; Kenneth C Pike; Susan M McCurry; Patricia Hunter; Joanne Maher; Lisa Snyder; Linda Teri
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2010-08-06       Impact factor: 4.077

Review 8.  [Alzheimer Disease].

Authors:  Fadi Massoud
Journal:  Can Fam Physician       Date:  2007-01       Impact factor: 3.275

9.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.

Authors:  Ming-Jang Chiu; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Ta-Fu Chen; Jen-Je Chieh; Hsin-Hsien Chen; Ting-Chi Chen; Chia-Shin Ho; Shuo-Fen Chang; Hao Chun Liu; Chin-Yih Hong; Hong-Chang Yang
Journal:  ACS Chem Neurosci       Date:  2013-10-23       Impact factor: 4.418

10.  Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada.

Authors:  Mark Oremus; Jean-Eric Tarride; Natasha Clayton; Parminder Raina
Journal:  BMC Health Serv Res       Date:  2009-12-29       Impact factor: 2.655
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.